High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.
Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda
{"title":"High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.","authors":"Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda","doi":"10.1093/neuonc/noaf049","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).</p><p><strong>Methods: </strong>Eighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.</p><p><strong>Results: </strong>The median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).</p><p><strong>Conclusions: </strong>SCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2147-2157"},"PeriodicalIF":13.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448793/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noaf049","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).
Methods: Eighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.
Results: The median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).
Conclusions: SCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.
期刊介绍:
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field.
The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.